Microbix Biosystems (TSX:MBX) Net Income From Continuing Operations : C$4.06 Mil (TTM As of Mar. 2024)

View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Microbix Biosystems's net income from continuing operations for the three months ended in Mar. 2024 was C$0.38 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was C$4.06 Mil.

Microbix Biosystems Net Income From Continuing Operations Historical Data

The historical data trend for Microbix Biosystems's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems Net Income From Continuing Operations Chart

Microbix Biosystems Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Net Income From Continuing Operations

Get a 7-Day Free Trial

0.03

-6.23

3.23

1.79

-0.04

Microbix Biosystems Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															0.03	-0.77	2.00	2.46	0.38

Microbix Biosystems Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$4.06 Mil.

Microbix Biosystems (TSX:MBX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

MBXBF:USA

Address

265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3

Website

https://www.microbix.com

Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.

Executives

James Stuart Currie

Senior Officer

Microbix Biosystems (TSX:MBX) Headlines

No Headlines